Show simple item record

dc.contributor.authorGutierrez-Bernays, David
dc.contributor.authorOstwald, Matthew
dc.contributor.authorAnstey, Chris
dc.contributor.authorCampbell, Victoria
dc.date.accessioned2021-12-20T05:55:15Z
dc.date.available2021-12-20T05:55:15Z
dc.date.issued2016
dc.identifier.issn1744-9979
dc.identifier.doi10.1111/1744-9987.12331
dc.identifier.urihttp://hdl.handle.net/10072/411084
dc.description.abstractRegional citrate anticoagulation (RCA) for continuous renal replacement therapy (CRRT) has recently been recommended as first-line over heparin. Evidence suggests that RCA prolongs filter life and may reduce bleeding risk, but there is little research on the benefits to dialysis dose delivery or cost, or the effectiveness of transitioning to RCA first-line. The aim of the present study was to assess the effect on dialysis delivery, cost and safety when transitioning from systemic heparin to RCA for first-line anticoagulation for CRRT. A single-center, retrospective observational study was conducted from 2006 to 2012, during which a transition from heparin to a simplified RCA protocol occurred. Demographic and dialysis data, pathology results and costs were obtained. Data were analyzed for both heparin and RCA, and for before and after the transition. 166 patients had 992 dialysis days (heparin 334 vs. RCA 658); demographics were well matched; RCA used less filters per day (P=0.03), had more days when prescribed dialysis was achieved (85% vs. 60%, P<0.001), and less filter "down-time" per day (2.4 vs. 6.1h, P=0.02). RCA was estimated to cost AU$487 per day, compared to heparin at $479 per day. When the data were analyzed, comparing before and after the transition, these results remained statistically significant. There was no statistical difference in clinical safety events. Transition to first-line RCA was safe, provided more time on filter and consumed less filter circuits using a simple and user friendly protocol. The adjusted cost difference appears negligible.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherWILEY-BLACKWELL
dc.relation.ispartofpagefrom53
dc.relation.ispartofpageto59
dc.relation.ispartofissue1
dc.relation.ispartofjournalTherapeutic Apheresis and Dialysis
dc.relation.ispartofvolume20
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchcode3202
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsHematology
dc.subject.keywordsUrology & Nephrology
dc.subject.keywordsAnticoagulation
dc.titleTransition From Heparin to Citrate Anticoagulation for Continuous Renal Replacement Therapy: Safety, Efficiency, and Cost
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationGutierrez-Bernays, D; Ostwald, M; Anstey, C; Campbell, V, Transition From Heparin to Citrate Anticoagulation for Continuous Renal Replacement Therapy: Safety, Efficiency, and Cost, Therapeutic Apheresis and Dialysis, 2016, 20 (1), pp. 53-59
dcterms.dateAccepted2015-05-22
dc.date.updated2021-12-20T05:53:29Z
gro.hasfulltextNo Full Text
gro.griffith.authorAnstey, Chris
gro.griffith.authorCampbell, Victoria


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record